跳至主要内容
临床试验/NCT07427407
NCT07427407
尚未招募
不适用

A Prospective, Non-Interventional, Observational Study to Collect Ultrasound Imaging Data for the Development of an AI-Based Software for the Detection and Visualization of Breast Biopsy Markers

AURA Health Technologies1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年5月1日最近更新:

概览

阶段
不适用
状态
尚未招募
发起方
AURA Health Technologies
入组人数
100
试验地点
1
主要终点
Successful Identification of Breast Biopsy Marker

概览

简要总结

The goal of this observational study is to collect ultrasound imaging data to support the development and refinement of an artificial intelligence (AI)-enhanced ultrasound software designed to detect and localize standard-of-care breast biopsy markers in adult female patients undergoing surgical excision of a breast tumor. The main questions it aims to answer are:

Can the study software identify the location of previously placed breast biopsy markers during routine ultrasound examinations?

Participants will undergo limited breast ultrasound imaging during a standard-of-care scheduled clinical visit. During the ultrasound imaging, the ultrasound system will automatically record the ultrasound images for the development and training of the AI software

The study does not change standard medical care, and no diagnostic or treatment decisions are made based on the study software.

详细描述

Study Design and Setting

This is a prospective, non-interventional observational study designed to collect ultrasound imaging data and related metadata to support the development, refinement, and performance characterization of an artificial intelligence (AI)-enhanced ultrasound software intended to detect and localize standard-of-care breast biopsy markers.

All ultrasound examinations are performed as part of routine clinical care for patients undergoing evaluation and planned surgical excision of a breast tumor. Study participation does not alter standard imaging protocols, clinical workflow, or treatment decisions.

Study Procedures

During a scheduled clinical visit, participants undergo limited B-mode breast ultrasound imaging using an FDA-cleared ultrasound system provided for the study. The system includes investigational software that displays marker localization output during image acquisition. The software output is not used to guide or alter clinical decision-making.

Ultrasound image data are automatically recorded by the system during the examination. Imaging datasets include visualization of the biopsy marker and surrounding breast tissue. When applicable, imaging may occur at different time points along the surgical treatment pathway.

A brief user-experience questionnaire may be completed by the operating physician following image acquisition. De-identified clinical and imaging metadata are recorded in a structured case report form (CRF).

Data Collection and Management

Ultrasound image data are de-identified prior to transfer. De-identified datasets are securely transmitted to the sponsor's controlled research environment for algorithm development and analysis.

Collected variables may include imaging parameters, marker type, breast tissue characteristics, tumor characteristics, and operator experience level. A structured data dictionary defines all variables collected, including source, format, allowable ranges, and coding conventions where applicable.

All study data are stored in compliance with applicable data protection and privacy regulations. Access to study data is restricted to authorized personnel.

Quality Assurance and Monitoring

Data quality procedures include predefined validation checks for completeness, internal consistency, and logical range limits within the electronic data capture system. Automated and manual data review processes are implemented to identify missing, inconsistent, or out-of-range values.

Source data verification may be performed on a risk-based sample of records to confirm consistency between recorded study data and source documents, such as medical records or ultrasound system exports.

Standard Operating Procedures (SOPs) govern study conduct, including patient recruitment, data acquisition, data transfer, data management, adverse event documentation, and change management. Monitoring activities may be conducted according to a risk-based plan.

Statistical Considerations

This study is primarily descriptive and developmental in nature. Analyses will focus on characterization of software marker localization performance, including measures such as detection success, time to localization, and performance across relevant subgroups (e.g., tissue characteristics, operator experience levels).

Agreement analyses may be performed comparing software output to trained reader assessments of recorded ultrasound images. Statistical methods may include descriptive statistics, confidence interval estimation, and exploratory subgroup analyses. The study is not designed as a confirmatory clinical effectiveness trial.

Sample Size Rationale

The planned enrollment is based on feasibility considerations and the need to collect a sufficient number of imaging datasets to support algorithm development and performance characterization across a range of clinical and anatomical conditions. The study is not powered for confirmatory hypothesis testing.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Participant can understand and sign informed consent documentation
  • Participant has a previous placement of one of the standard-of-care breast biopsy markers

排除标准

  • Previous breast cancer surgery in the region of interest
  • Life expectancy \<6 months
  • Allergy and/or hypersensitivity to titanium and/or nickel and/or ultrasound gel
  • Carcinoma unknown primary
  • Patient does not accept ultrasound examinations
  • Patient with skin disease of areas to be examined (breast and/or axillary)

研究组 & 干预措施

Single Observational Cohort

Adult female patients undergoing routine breast ultrasound imaging in a clinical care setting who have a previously placed standard-of-care breast biopsy marker.

干预措施: Breast Ultrasound Imaging With Investigational AI Software (Device)

结局指标

主要结局

Successful Identification of Breast Biopsy Marker

时间窗: During the ultrasound imaging examination (single imaging session; approximately 5-10 minutes)

Whether the investigational software identifies the location of a previously placed standard-of-care breast biopsy marker during ultrasound imaging.

次要结局

未报告次要终点

研究者

发起方
AURA Health Technologies
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验